Entity

Time filter

Source Type

Luoyang, China

Yang Y.,Shandong University | Yan M.,Shandong University | Zhang H.,Interventional Center | Wang X.,Shandong University
Experimental and Therapeutic Medicine | Year: 2013

Studies have indicated that the immune system plays a pivotal role in hepatitis. Substance P (SP) has been shown to modulate the immune response. In order to investigate the role of SP in liver injury and to determine whether it leads to pro-inflammatory signaling, we established a mouse model of hepatic injury induced by concanavalin A (ConA). We also exposed mouse Kupffer cells (KCs) to SP in vitro. Cytokine and SP levels in liver homogenates were detected using enzyme-linked immunosorbent assay (ELISA) and the protective effects of L-703,606 were evaluated through serological and histological assessments. Neurokinin-1 receptor (NK-1R) expression was evaluated by immunofluorescence and quantitative polymerase chain reaction (PCR). The levels of SP, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly increased in the ConA-treated mice and the levels of ALT and AST were markedly reduced by L-703,606-pretreatment. Liver injury was significantly reduced by treatment with L-703,606. The mouse KCs expressed NK-1R and SP increased NK-1R mRNA expression. Furthermore, NK-1R blockade eliminated the effect of SP on NK-1R mRNA expression. The cytokine levels exhibited a substantial increase in the SP-pretreated KCs compared with the KCs that were cultured in control medium. The interleukin (IL)-6 and tumor necrosis factor (TNF)-α levels in the L-703,606-pretreated KCs were significantly lower compared with those in the SP-pretreated KCs. Our study suggests that neurogenic inflammation induced by SP plays an important role in hepatitis. Mouse KCs express NK-1R and SP increases NK-1R mRNA expression. SP enhances IL-6 and TNF-α secretion and an NK-1R antagonist inhibits this secretion. Source


Djenouri D.,CERIST Research Center | Djenouri D.,Norwegian University of Science and Technology | Balasingham I.,Norwegian University of Science and Technology | Balasingham I.,Interventional Center
DCOSS '10 - International Conference on Distributed Computing in Sensor Systems, Adjunct Workshop Proceedings: IWSN, MobiSensors, Poster and Demo Sessions | Year: 2010

This paper presents the design and implementation of a new geographical quality of service (QoS) routing for wireless sensor networks. The protocol is based on traffic differentiation and provides customized QoS according to the traffic requirement. For each packet, the protocol attempts to fulfill the required data-related QoS metric(s) while considering power-efficiency. The data related metrics include packet latency and reliability, while power-efficiency has been considered for both power transmission minimization and residual energy maximization (load balancing). The protocol has been implemented in real sensor motes using Contiki operating system, which offers many modules and has many features that facilitate efficient communication protocol implementation. The protocol was then evaluated in a testbed. The experimental results show good QoS performance, and particularly, traffic-differentiation QoS as expected, i.e., QoS-sensitive packets were routed with better performances than regular packets. The protocol is generic and applies to any application with traffic requiring different QoS, such as in biomedical and vehicular applications. ©2010 IEEE. Source


Sundset A.,Rikshospitalet | Sundset A.,Interventional Center | Lund M.B.,Rikshospitalet | Hansen G.,Rikshospitalet | And 6 more authors.
Respiration | Year: 2012

Background: Airway complications remain a significant cause of morbidity after lung transplantation. The majority of the centres that have published their results have used metal stents. Objectives: We report the long-term outcome of silicone stenting and subsequent stent removal in lung transplant recipients with stenotic airway complications. Method: From 1990 to 2008, 279 patients received 88 single, 170 double, and 21 heart-and-lung transplantations. Of 470 anastomoses at risk, 44 airway complications developed and were treated in 35 patients. Six lesions were treated with Nd:YAG laser and balloon dilatations only. Thirty-two silicone stents of Hood or Dumont type were inserted in 27 patients. Results: Symptoms were relieved and FEV 1 increased in all patients (median 0.7 litres, range 0.1-1.8 litres, p < 0.0001). In 8 patients, stents had to be repositioned or reinserted, in 19 patients only one insertion and one removal procedure were necessary. One patient suffered a serious complication with haemorrhage and pneumonectomy, 3 patients had minor airway wall injuries resolving spontaneously. Six patients died with the stents from causes not related to the airway complications. Twenty-five stents could be removed after a median of 6 months (range 1-22) in 21 patients, and 22 airways remained patent. Median FEV 1 was 2.3 litres immediately after stent removal, and remained 2.3 litres after 24 months. Conclusion: Stenotic airway complications after lung transplantation can be successfully treated with silicone stents, which can ultimately be removed, leaving a patent airway. Copyright © 2012 S. Karger AG, Basel. Source


Cai D.-S.,Interventional Center | Gong X.-P.,Interventional Center
International Journal of Ophthalmology | Year: 2010

• AIM: To discuss the value of CT in diagnosing benign tumor of the lacrimal gland. • METHODS: The clinical data and imaging manifestations of 30 cases with pathologically confirmed benign lacrimal gland tumor were analyzed retrospectively. • RESULTS: The lesions originated in the orbital lobe of the lacrimal gland in 26 cases and the palpebral lobe in 4 cases. The tumors showed oval shape in 18 cases, irregular shape in 4 cases, irregular margin shape in 8 cases. Most cases showed average density on CT. Orbital bone compression or defect was seen in 18 cases, bone destruction with hyperostosis bone sclerosis in 12 cases. • CONCLUSION: Benign tumos in the lacrimal gland have some imaging features. Source


De Waha A.,TU Munich | Dibra A.,TU Munich | Kufner S.,TU Munich | Baumgart D.,Preventicum Klinik fur Diagnostik | And 4 more authors.
Clinical Research in Cardiology | Year: 2011

Background Although it is widely believed that patients with diabetes mellitus obtain the greatest benefit from drug-eluting stents, convincing evidence on long-term efficacy and safety of these stents is lacking. Methods We performed a meta-analysis of individual patient data from four randomized trials including 583 patients comparing sirolimus eluting with bare metal stents (median follow-up of 4.2 years). These were the only specific trials reporting on drug-eluting stents in diabetic patients. The primary endpoint was the incidence of major cardiac events. The secondary endpoints were all-cause mortality and myocardial infarction as a safety endpoint and target lesion re-intervention as an efficacy endpoint. Stent thrombosis was also evaluated. Results There was a significant reduction in the overall hazard of major cardiac events (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.36-0.63, P < 0.001) with sirolimus-eluting stents. This was mostly due to a significant reduction in the overall hazard of repeat revascularization (HR 0.27, 95% CI 0.18-0.41, P < 0.001) in favor of sirolimus-eluting stents. However, the overall hazard of death (HR 0.91, 95% CI 0.59-1.41, P = 0.68) as well as death or myocardial infarction (HR 0.77, 95% CI 0.54-1.09, P = 0.14) were not significantly different between the groups. No significant differences were observed regarding stent thrombosis (HR 0.50, 95% CI 0.15-1.69, P = 0.26). Conclusions Sirolimus-eluting stents are highly effective in reducing the risk for major cardiac events and safe in diabetic patients with coronary artery disease. © Springer-Verlag 2011. Source

Discover hidden collaborations